

Carprieve 50mg  
50 x Blister Carton  
Label file name: 54884\_44396\_50B\_primary\_MPL\_V1.pdf  
100% Actual 1:1 Size = 55 x 22.5 x 130mm  
(100% when printed on A4 paper)  
16/6/08

Blister  
Blister

000000001

**READ ENGLISH REARLET  
BEFORE USING THIS PRODUCT**

**PRESENTATION**  
A white to off-white circular tablet for oral administration containing 50 mg carprofen.

**USES**  
A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs, for example in degenerative joint diseases.

**DIRECTIONS FOR USE**  
For oral administration only.  
Contraindications:  
This product is contraindicated for use in the cat.  
This product is contraindicated for use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

**Precautions:**  
**DO NOT** exceed the stated dose. All dogs should undergo a thorough clinical examination and appropriate laboratory tests before introduction of NSAID therapy. During extended administration, appropriate re-evaluation and laboratory tests should be undertaken periodically.  
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.  
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.  
Avoid administration concurrently with other NSAIDs or corticosteroids. Appropriate 'washout' time should be allowed when changing therapy. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.  
Concurrent administration of potential nephrotoxic drugs should be avoided.  
Specific studies to establish the safety of this product in breeding, pregnant or lactating bitches have not been undertaken, therefore use in these classes of dogs is not recommended or should be done with caution.  
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antibiotic therapy should be instigated.



**Dosage and Administration:**  
Doses 2 to 4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response of the condition under treatment. Initial therapy at 4 mg/kg bodyweight per day given in 2 equally divided doses is generally recommended. Subject to clinical response, the dose may be reduced to 2 mg/kg bodyweight per day administered as a once daily dose.

**FIRST AID**  
If poisoning occurs, contact a doctor or Poisons Information Centre, Phone Australia 131126.

Store below 25°C (Air conditioning) in a dry place. Protect from light.

Make in the UK for  
Norbrook Laboratories Australia  
Pty Limited  
A.C.N. 060 872 688  
Unit 7/1 Trade Park Drive  
Tullamarine, VIC 3042  
Free Call: 1800 365 369  
APVMA: 54884/SUB4068


**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**


**CARPRIEVE 50 mg Tablets  
For Dogs**

**Each Tablet contains  
50 mg CARPROFEN**  
A non-steroidal anti-inflammatory  
drug for the relief of pain and  
inflammation in dogs.

**5 Blister strips containing  
10 tablets per strip**







**CARPRIEVE 50 mg Tablets  
For Dogs**

 0 000000 000000 1

**CARPRIEVE 50 mg Tablets  
For Dogs**



**Carprieve 50mg**  
**100 x Blister Carton**  
 Label file name: 54884\_44396\_100B\_primary\_MPL\_V1.pdf  
 100% Actual 1:1 Size = 55 x 40 x 130mm  
 (66% when printed on A4 and  
 100% when printed on A3 paper)  
 12/6/08

Empty: Batch:		00000001
<b>PRESCRIPTION ANIMAL REMEDY</b> <b>KEEP OUT OF REACH OF CHILDREN</b> <b>FOR ANIMAL TREATMENT ONLY</b>	<b>READ ENCLOSED LEAFLET BEFORE</b> <b>USING THIS PRODUCT</b>	<b>PRESCRIPTION ANIMAL REMEDY</b> <b>KEEP OUT OF REACH OF CHILDREN</b> <b>FOR ANIMAL TREATMENT ONLY</b>
<b>CARPRIEVE 50 mg Tablets</b> <b>For Dogs</b>	<p><b>PRESENTATION</b> A white/off-white circular tablet for oral administration containing 50 mg carprofen.</p> <p><b>USES</b> A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs, for example in degenerative joint disease.</p> <p><b>DIRECTIONS FOR USE</b> For oral administration only. Contraindications: This product is contraindicated for use in the cat. This product is contraindicated for use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.</p> <p><b>Precautions:</b> DO NOT exceed the stated dose. All dogs should undergo a thorough clinical examination and appropriate laboratory tests before introduction of NSAID therapy. During extended administration, appropriate re-evaluation and laboratory tests should be undertaken periodically. Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. Avoid administration concurrently with other NSAIDs or corticosteroids. Appropriate 'washout' time should be allowed when changing therapy. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.</p>	 <b>CARPRIEVE 50 mg Tablets</b> <b>For Dogs</b>
<p>Each Tablet contains <b>50 mg CARPROFEN</b> A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs.</p> <p style="text-align: center;">10 Blister strips containing 10 tablets per strip</p>	<p>Each Tablet contains <b>50 mg CARPROFEN</b> A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs.</p> <p style="text-align: center;">10 Blister strips containing 10 tablets per strip</p>	<p>Concurrent administration of potential nephrotoxic drugs should be avoided. Specific studies to establish the safety of this product in breeding, pregnant or lactating bitches have not been undertaken, therefore use in these classes of dogs is not recommended or should be done with caution. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.</p> <p><b>Dosage and Administration:</b> Dosage: 2 to 4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response of the condition under treatment. Initial therapy at 4 mg/kg bodyweight per day given in 2 equally divided doses is generally recommended. Subject to clinical response, the dose may be reduced to 2 mg/kg bodyweight per day administered as a once daily dose.</p> <p><b>FIRST AID</b> If poisoning occurs, contact a doctor or Poisons Information Centre, Phone Australia 131126.</p> <p>Store below 25°C (At room temperature) in a dry place. Protect from light.</p> <p>Made in the UK for Norbrook Laboratories Australia Pty Limited A.C.N. 080 972 580 Unit 7/1 Trade Park Drive Tullamarine, VIC 3043 Free Call: 1800 995 995 APVMA: 54884/100B/0408</p>
		 0 000000 000000
<b>PRESCRIPTION ANIMAL REMEDY</b> <b>KEEP OUT OF REACH OF CHILDREN</b> <b>FOR ANIMAL TREATMENT ONLY</b>	<b>PRESCRIPTION ANIMAL REMEDY</b> <b>KEEP OUT OF REACH OF CHILDREN</b> <b>FOR ANIMAL TREATMENT ONLY</b>	<b>PRESCRIPTION ANIMAL REMEDY</b> <b>KEEP OUT OF REACH OF CHILDREN</b> <b>FOR ANIMAL TREATMENT ONLY</b>
<b>CARPRIEVE 50 mg Tablets</b> <b>For Dogs</b>	<b>CARPRIEVE 50 mg Tablets</b> <b>For Dogs</b>	<b>CARPRIEVE 50 mg Tablets</b> <b>For Dogs</b>

Carprieve 50mg  
100 Tablet Label  
Label file name: 54884\_44396\_100T\_immediate\_MPL\_V1.pdf  
100% Actual 1:1 Size = 33 x 89mm  
(100% when printed on A4 paper)  
16/6/08

<b>READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT</b>	<b>PRESCRIPTION ANIMAL REMEDY</b> KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY	Made in the UK for Norbrook Laboratories Australia Pty Ltd. A.C.N. 080 972 596 Unit 7/1 Trade Park Drive Tullamarine, VIC 3043 Free call: 1800 665 866
<b>DIRECTIONS FOR USE</b> Dose: 2-4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response. See leaflet for full details.	<b>CARPRIEVE 50 mg Tablets For Dogs</b> Each Tablet contains 50 mg CARPROFEN A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs.	APVMA: 54884/100T/0408
Store below 25°C (Air conditioning) in a dry place out of direct sunlight.	100 Tablets <b>Norbrook</b>	Batch: Expiry: 



**CARPRIEVE 50 mg Tablets**  
**For Dogs**

**PRESCRIPTION ANIMAL REMEDY**  
**KEEP OUT OF REACH OF CHILDREN**  
**FOR ANIMAL TREATMENT ONLY**

**PRESCRIPTION ANIMAL REMEDY**  
**KEEP OUT OF REACH OF CHILDREN**  
**FOR ANIMAL TREATMENT ONLY**

**CARPRIEVE 50 mg Tablets**  
**For Dogs**

**Each Tablet contains**  
**50 mg CARPROFEN**

A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs.

**25 Blister strips containing**  
**10 tablets per strip**



**Carprieve 50mg**  
**250 x Blister Carton**  
Label file name: 54884\_44396\_250B\_primary\_MPL\_V1.pdf  
100% Actual 1:1 Size = 120 x 58 x 133mm  
(66% when printed on A4 and  
100% when printed on A3 paper)  
12/6/08

000000C01

**PRESCRIPTION ANIMAL REMEDY**  
**KEEP OUT OF REACH OF CHILDREN**  
**FOR ANIMAL TREATMENT ONLY**



**CARPRIEVE 50 mg Tablets**  
**For Dogs**

**Each Tablet contains**  
**50 mg CARPROFEN**

A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs.

**25 Blister strips containing**  
**10 tablets per strip**



Concurrent administration of potential nephrotoxic drugs should be avoided. Specific studies to establish the safety of this product in breeding, pregnant or lactating bitches have not been undertaken, therefore use in these classes of dogs is not recommended or should be done with caution. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

**Dosage and Administration:**  
Dosage: 2 to 4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response of the condition under treatment. Initial therapy at 4 mg/kg bodyweight per day given in 2 equally divided doses is generally recommended. Subject to clinical response, the dose may be reduced to 2 mg/kg bodyweight per day administered as a once daily dose.

**FIRST AID**  
If poisoning occurs, contact a doctor or Poisons Information Centre, Phone Australia 131126.

Store below 25°C (Air conditioning) in a dry place. Protect from light.

Made in the UK for  
Norbrook Laboratories Australia Pty Limited  
A.C.N. 080 972 598  
Unit 7/1 Trade Park Drive  
Tullamarine, VIC 3043  
Free Call: 1800 885 888

APVMA: 54884/250B/0405

Batch:  
Expiry:





Carprieve 50mg  
250 Tablet Label  
Label file name: 54884\_44396\_250T\_immediate\_MPL\_V1.pdf  
100% Actual 1:1 Size = 49 x 131.75mm  
(100% when printed on A4 paper)  
12/6/08

**READ THE ENCLOSED LEAFLET  
BEFORE USING THIS PRODUCT**

**DIRECTIONS FOR USE**

**Dosage:** 2-4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response. See leaflet for full details.

Store below 25°C (Air conditioning) in a dry place out of direct sunlight.

**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**

**CARPRIEVE 50 mg Tablets  
For Dogs**

Each Tablet contains  
**50 mg CARPROFEN**  
A non-steroidal anti-inflammatory drug for  
the relief of pain and inflammation in dogs.

**250 Tablets**



Made in the UK for  
Norbrook Laboratories Australia Pty  
Limited  
A.C.N. 080 972 596  
Unit 7/1 Trade Park Drive  
Tullamarine  
VIC 3043  
Free call: 1800 665 866  
APVMA: 54884/250T/0408

Batch:  
Expiry:



000000L01



Carprieve 50mg  
500 x Blister Carton  
Label file name: 54884\_44396\_500B\_primary\_MPL\_V1.pdf  
100% Actual 1:1 Size = 205 x 57 x 135mm  
(50% when printed on A4 and  
74% when printed on A3 paper)  
27/1/10

000000C11

**PRESCRIPTION ANIMAL REMEDY**  
**KEEP OUT OF REACH OF CHILDREN**  
**FOR ANIMAL TREATMENT ONLY**

**CARPRIEVE 50 mg Tablets**  
**For Dogs**

Each Tablet contains  
**50 mg CARPROFEN**  
A non-steroidal anti-inflammatory drug for the relief  
of pain and inflammation in dogs.

**50 Blister strips containing**  
**10 tablets per strip**



**READ ENCLOSED LEAFLET BEFORE USING THIS PRODUCT**

**PRESENTATION**  
A white/off-white circular tablet for oral administration containing 50 mg carprofen.

**USES**  
A non-steroidal anti-inflammatory drug for the relief of pain and inflammation in dogs, for example in degenerative joint disease.

**DIRECTIONS FOR USE**  
For oral administration only.  
**Contraindications:**  
This product is contraindicated for use in the cat.  
This product is contraindicated for use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

**Precautions:**  
DO NOT exceed the stated dose.  
All dogs should undergo a thorough clinical examination and appropriate laboratory tests before introduction of NSAID therapy. During extended administration, appropriate re-evaluation and laboratory tests should be undertaken periodically.  
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.  
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.  
Avoid administration concurrently with other NSAIDs or corticosteroids. Appropriate 'washout' time should be allowed when changing therapy. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

**PRESCRIPTION ANIMAL REMEDY**  
**KEEP OUT OF REACH OF CHILDREN**  
**FOR ANIMAL TREATMENT ONLY**

**CARPRIEVE 50 mg Tablets**  
**For Dogs**

Each Tablet contains  
**50 mg CARPROFEN**  
A non-steroidal anti-inflammatory drug for the relief  
of pain and inflammation in dogs.

**50 Blister strips containing**  
**10 tablets per strip**



Concurrent administration of potential nephrotoxic drugs should be avoided. Specific studies to establish the safety of this product in breeding, pregnant or lactating bitches have not been undertaken, therefore use in these classes of dogs is not recommended or should be done with caution. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

**Dosage and Administration:**  
Dosage: 2 to 4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response of the condition under treatment. Initial therapy at 4 mg/kg bodyweight per day given in 2 equally divided doses is generally recommended. Subject to clinical response, the dose may be reduced to 2 mg/kg bodyweight per day administered as a once daily dose.

**FIRST AID**  
If poisoning occurs, contact a doctor or Poisons Information Centre, Phone Australia 131126.

Store below 25°C (Air conditioning) in a dry place. Protect from light.

Made in the UK for  
Norbrook Laboratories Australia Pty Limited  
A.C.N. 090 972 598  
Unit 7/1 Trade Park Drive  
Tullamarine, VIC 3043  
Free Call: 1800 965 888

APVMA: 54884/500B/D40B

Batch:  
Expiry:



Carprieve 50mg  
500 Tablet Label  
Label file name: 54884\_44396\_500T\_immediate\_MPL\_V1.pdf  
100% Actual 1:1 Size = 49 x 131.75mm  
(100% when printed on A4 paper)  
12/6/08

**READ THE ENCLOSED LEAFLET  
BEFORE USING THIS PRODUCT**

**DIRECTIONS FOR USE**

**Dosage:** 2-4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response. See leaflet for full details.

Store below 25°C (Air conditioning) in a dry place out of direct sunlight.

**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**

**CARPRIEVE 50 mg Tablets  
For Dogs**

Each Tablet contains  
**50 mg CARPROFEN**  
A non-steroidal anti-inflammatory drug for  
the relief of pain and inflammation in dogs.

**500 Tablets**



Made in the UK for  
Norbrook Laboratories Australia Pty  
Limited  
A.C.N. 080 972 596  
Unit 7/1 Trade Park Drive  
Tullamarine  
VIC 3043  
Free call: 1800 665 866  
APVMA: 54884/500T/0408

Batch:  
Expiry:



00000001

Carprieve 50mg  
Blister Foil

Label file name: 54884\_44396\_50mg\_immediate\_MPL\_V1.pdf  
100% Actual 1:1 Size = 50 x 124mm  
(100% when printed on A4 paper)  
17/6/08





# Carprieve Tablets

## Leaflet

File name: 54884\_48988\_leaflet\_MPL\_V1.pdf

100% Actual 1:1 Size = 148 x 210 mm

(100% when printed on A4 paper)

Page 1 of 2

8/12/09

**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**

### **CARPRIEVE 20 mg Tablets for Dogs CARPRIEVE 50 mg Tablets For Dogs CARPRIEVE 100 mg Tablets For Dogs**


#### **INDICATIONS**

The active ingredient in CARPRIEVE Tablets for Dogs, carprofen, is a non-steroidal, anti-inflammatory drug for the relief of pain and inflammation in dogs.

#### **PRODUCT DESCRIPTION**

CARPRIEVE Tablets are presented as circular, white/off-white tablets for oral administration to dogs. Each tablet contains either 20 mg, 50 mg or 100mg carprofen in a palatable base.

CARPRIEVE Tablets contain carprofen, a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class. The chemical name for carprofen, a substituted carbazole, is (±)-6-chloro-α-methylcarbazole-2-acetic acid. The structural formula is:



Carprofen is a white, crystalline compound with an empirical formula of  $C_{18}H_{12}NO_2Cl$  and a molecular weight of 273.72. It is freely soluble in ethanol, but practically insoluble in water at 25°C.

#### **CLINICAL PHARMACOLOGY:**

Carprofen is a non-narcotic, non-steroidal, anti-inflammatory drug with characteristic analgesic and antipyretic activity, approximately equipotent to indomethacin in animal models<sup>1</sup>.

As with other NSAIDs, the exact mode of action of carprofen has not been established; however, inhibition of prostaglandin synthesis accounts for at least part of its mechanism of action<sup>2</sup>.

Carprofen is a moderately potent inhibitor of phospholipase  $A_2$  and a reversible inhibitor of cyclooxygenase<sup>3</sup>.

Two unique cyclooxygenases have been described in mammals<sup>4</sup>. The constitutive cyclooxygenase, COX-1, synthesises prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. The specificity of a particular NSAID for either COX-2 or COX-1 may vary from species to species. In an *in vitro* study using canine cell cultures, carprofen demonstrated a greater than 100-fold selective inhibition of COX-2 compared with COX-1<sup>5</sup>. Carprofen has also been shown to inhibit the release of several prostaglandins in two inflammatory cell systems: rat polymorphonuclear leukocytes (PMN) and human rheumatoid synovial cells, indicating inhibition of acute (PMN system) and chronic (synovial cell system) inflammatory reactions<sup>1</sup>.

In mice, carprofen has been shown to be a much weaker blocker of castor oil induced diarrhoea and arachidonic acid-induced toxicity than indomethacin<sup>2</sup>.

This decreased effect of carprofen on prostaglandin synthesis in the gastrointestinal tract may explain its relatively low ulcerogenic activity compared to other drugs in its class<sup>1,5</sup>.

Several studies have demonstrated that carprofen has modulatory effects on both humoral and cellular immune responses<sup>7,8,9,10</sup>.

Data also indicate that carprofen inhibits the production of osteoclast-activating factor (OAF),  $PGE_1$ , and  $PGE_2$  by its inhibitory effects on prostaglandin biosynthesis<sup>1</sup>.

Whole blood clotting times were evaluated in dogs given carprofen at a dose rate of 9 mg/kg once daily for 14 days. At all observations both prior to and during treatment, the mean clotting times remained within the range of normal values<sup>11</sup>.

Based upon comparison with data obtained from intravenous administration, carprofen is rapidly and nearly completely absorbed (more than 90% bioavailable) when administered orally<sup>11,12</sup>.

The mean terminal half-life of carprofen is approximately 8 hours (range 4.5 – 9.8 hours) after single oral doses varying from 1-25 mg/kg of bodyweight.

After a 100 mg single intravenous bolus dose, the mean elimination half-life was approximately 11.7 hours in the dog<sup>12</sup>.

Carprofen is more than 99% bound to plasma protein and exhibits a very small volume of distribution<sup>12</sup>.

Carprofen is eliminated in the dog primarily by biotransformation in the liver followed by rapid excretion of the resulting metabolites (the ester glucuronide of carprofen and the ether glucuronides of 2 phenolic metabolites, 7-hydroxy carprofen and 8-hydroxy carprofen) in the faeces (70-80%) and urine (10-20%)<sup>13</sup>.

Some enterohepatic circulation of the drug has been observed. Studies have not revealed any evidence of chiral inversion of carprofen enantiomers<sup>14,15</sup>.

#### **DIRECTIONS FOR USE:**

For oral administration only.

#### **CONTRAINDICATIONS:**

**This product is contraindicated for use in the cat. The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog, and the therapeutic index is narrower. In the absence of specific data, the use of CARPRIEVE Tablets in the cat is contraindicated. This product is contraindicated for use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. This product is contraindicated for use in dogs exhibiting previous hypersensitivity to carprofen.**

#### **PRECAUTIONS:**

DO NOT exceed the stated dose.

All dogs should undergo a thorough clinical examination and appropriate laboratory tests before introduction of NSAID therapy. During extended administration, appropriate re-evaluation and laboratory tests should be undertaken periodically.

Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

Avoid administration concurrently with other NSAIDs or corticosteroids. Appropriate 'washout' time should be allowed when changing therapy. If changing

anti-inflammatory products, take into account the pharmacokinetic properties of the drugs used previously when considering the delay period between the individual drugs. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

Specific studies to establish the safety of this product in breeding, pregnant or lactating bitches have not been undertaken, therefore use in these classes of dogs is not recommended or should be done with caution.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Effects

Infopest

Verified



# Carprieve Tablets Leaflet

File name: 54884\_48988\_leaflet\_MPL\_V1.pdf  
100% Actual 1:1 Size = 148 x 210 mm  
(100% when printed on A4 paper)  
Page 2 of 2  
8/12/09

may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase, which is responsible for the formation of prostaglandins from arachidonic acid. When NSAIDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients. Sensitivity to drug-associated adverse effects varies with the individual patient. NSAID therapy could unmask occult disease, which has previously been undiagnosed due to the absence of clinical signs.

CARPRIEVE Tablets should be used with caution in dogs with bleeding disorders (eg. Von Willebrand's disease), as safety has not been established in dogs with these disorders. The safe use of CARPRIEVE Tablets in pregnant and lactating bitches and dogs used for breeding purposes has not been established. Studies to determine the activity of CARPRIEVE Tablets when administered concurrently with other protein-bound drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring additional therapy.

#### **SIDE EFFECTS:**

Carprofen is an NSAID, and as with others in the class, adverse reactions may occur with its use. Typical adverse reactions of NSAIDs include loss of appetite, vomiting, diarrhoea, melæna or faecal occult blood and lethargy. Events involving suspected renal, haematological, neurological, dermatological and hepatic effects have also been reported. Symptomatic treatment may be necessary. In rare cases death has been reported. In most cases, side effects are transient and disappear following termination of treatment. Owners should be advised to discontinue therapy and contact their veterinary surgeon immediately if signs of intolerance are observed.

#### **DOSAGE AND ADMINISTRATION:**

##### **For oral administration only**

Dosage: 2 to 4 mg/kg bodyweight per day. Dose, frequency and duration of treatment will be dependent upon clinical response of the condition under treatment. Initial therapy at 4 mg/kg bodyweight per day given in 2 equally divided doses is generally recommended. Subject to clinical response, the dose may be reduced to 2 mg/kg bodyweight per day administered as a once daily dose.

#### **FIRST AID**

If poisoning occurs, contact a doctor or Poisons Information Centre, Phone Australia 131126.

#### **Disposal:**

Dispose of empty containers or expired product by wrapping with paper and putting in garbage.

#### **Presentation:**

CARPRIEVE 20 mg Tablets:  
100 tablets per securitainer  
500 tablets per securitainer  
10 Blister strips containing 10 tablets per strip  
50 Blister strips containing 10 tablets per strip

CARPRIEVE 50 mg Tablets:  
100 tablets per securitainer  
250 tablets per securitainer  
500 tablets per securitainer  
5 Blister strips containing 10 tablets per strip  
10 Blister strips containing 10 tablets per strip  
25 Blister strips containing 10 tablets per strip  
50 Blister strips containing 10 tablets per strip

CARPRIEVE 100mg Tablets:  
14 tablets per securitainer  
30 tablets per securitainer  
100 tablets per securitainer  
1 Blister strips containing 10 tablets per strip  
2 Blister strips containing 10 tablets per strip  
3 Blister strips containing 10 tablets per strip  
5 Blister strips containing 10 tablets per strip

6 Blister strips containing 10 tablets per strip  
7 Blister strips containing 10 tablets per strip  
10 Blister strips containing 10 tablets per strip  
14 Blister strips containing 10 tablets per strip  
18 Blister strips containing 10 tablets per strip  
20 Blister strips containing 10 tablets per strip  
25 Blister strips containing 10 tablets per strip  
30 Blister strips containing 10 tablets per strip  
50 Blister strips containing 10 tablets per strip  
100 Blister strips containing 10 tablets per strip

Norbrook Laboratories Australia Pty Limited  
A.C.N. 080 972 596  
Unit 7/1 Trade Park Drive  
Tullamarina, VIC 3043  
Free Call: 1800 665 866



#### **Storage:**

Store below 25°C (Air conditioning) in a dry place out of direct sunlight.

#### **APVMA Approval Numbers:**

CARPRIEVE 20 mg Tablets for Dogs 54885 /1209  
CARPRIEVE 50 mg Tablets for Dogs 54884 /1209  
CARPRIEVE 100mg Tablets for Dogs 63022/1209

#### **REFERENCES:**

- Baruth H, Berger L, Bradshaw D, Cashin CH, Coffey JW, Gupta N, Konikoff J, Roberts NA and Wylar-Plaut R (1986)  
Carprofen. IN: *Anti-inflammatory and Anti-rheumatic Drugs*, Vol. II, Newer Anti-inflammatory Drugs, Rainsford KD, ed. CRC Press, Boca Raton, P. 33-47.
- Ricketts AP, Lundy KM and Seibel SB (1998).  
Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. *Am J Vet Res* 59(11):1441-6.
- Hope WC and Walton AF (1983)  
Comparison of nonsteroidal anti-inflammatory drugs as inhibitors of phospholipase A<sub>2</sub> (Abstract). *Fed Proc Am Soc Exp Biol* 42:875.
- Masferrer JL, Isakson PC and Saibert K (1996)  
Cyclooxygenase-2 inhibitors. A new class of anti-inflammatory agents that spare the gastrointestinal tract. *Gastroenterology Clin North Am* 25:363-372.
- Strub KM and Muller RKM (1979)  
Relation between ulcerogenic activity of various NSAIDs and their potency as inhibitors of prostaglandin synthesis *in vivo*. IN: *Arachidonic Acid Metabolism in Inflammation and Thrombosis*. Brune K, Baggliolini M, eds. Birkhauser Verlag, Basel, Pp 245-253.
- Randall LD and Baruth H (1976)  
Analgesic and Anti-inflammatory Activity of 6-Chloro-Alpha-Methyl-Carbazole-2-Acetic Acid (C-5720). *Arch Int Pharmacodyn* 220:94-114.
- Cauppens JL, Rodriguez MA and Goodwin JS (1982)  
Non-steroidal anti-inflammatory agents inhibit the synthesis of IgM rheumatoid factor *in vitro*. *Lancet* 1(8271):528-530.
- Cauppens JL and Goodwin JS (1982)  
Endogenous prostaglandin E<sub>2</sub> enhances polyclonal immunoglobulin production by tonically inhibiting T suppressor cell activity. *Cellular Immunology* 70:41-54.
- Schleimer RP and Benjamini E (1981)  
Effects of prostaglandin synthesis inhibition on the immune response. *Immunopharmacology* 3:205-218.
- Vait BC (1982)  
Immunoregulatory activity of cultured-induced suppressor macrophages. *Cellular Immunology* 72:14-27.
- McKellar DA, Pearson T, Bogan JA, Galbraith EA, Lees P, Ludwig B and Tiborghien MP (1990)  
Pharmacokinetics, tolerance and serum thromboxane inhibition of carprofen in the dog. *Journal of Small Animal Practice* 31:443-448.
- Schmitt M and Guentert W (1990)  
Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. *Biopharm Drug Dispos* 11(7):585-594.
- Rubio F, Seawall S, Pocolinko R, DeBarbieri B, Benz W, Berger L, Morgan L, Pao J, Williams TH and Koechlin B (1990)  
Metabolism of carprofen, a nonsteroidal anti-inflammatory agent, in rats, dogs, and humans. *J Pharmaceutical Sciences* 69:1245-1253.
- Prymenko N, Garnier F, Ferré JP, Delatour P and Toutain PL (1998)  
Enantioselectivity of the enterohepatic recycling of carprofen in the dog. *Drug Metab Dispos* 26(2):170-4.
- McKellar DA, Delatour P and Lees P (1994)  
Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. *J Vet Pharmacol Therap* 17(8):447-54.